Biotech Values

[DewDiligence]

>> I disagree with your thumbs up as a modest negative. Approval sets a bar. If squal is as good as everyone thinks, i.e. superior efficacy with less invasive delivery, let pfizer pave the way for genr. The better macugen does, the better it is for any clearly superior fast followers. imo. <<

No problem, that’s why we have a market! I think the drawback of having an entrenched competitor outweighs the “lowering the bar” effect, which I don’t really subscribe to in the first place.